Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burak Yulug

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Life Sciences|December 29, 2022
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseasesHasan Turkez, Ozlem Altay, Serkan Yildirim, et al.
Translational Neurodegeneration|January 26, 2023
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trialBurak Yulug, Ozlem Altay, Xiangyu Li, et al.
Brain Communications|January 16, 2025
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trialBurak Yulug, Ozlem Altay, Xiangyu Li, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Life Sciences|December 29, 2022
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseasesHasan Turkez, Ozlem Altay, Serkan Yildirim, et al.
Translational Neurodegeneration|January 26, 2023
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trialBurak Yulug, Ozlem Altay, Xiangyu Li, et al.
Brain Communications|January 16, 2025
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trialBurak Yulug, Ozlem Altay, Xiangyu Li, et al.
Pageof 9